dromlakhani Recommend RT-CGM for well-controlled T1DM
STEP 1 — Gather Information
Collect patient age, diabetes type, most recent A1C, willingness and ability to wear RT-CGM sensor nearly daily, history of skin adhesives allergies, current glucose monitoring frequency, hypoglycemia awareness, and any psychosocial or financial barriers.
Action: Document A1C, device willingness/ability, and contraindications.
STEP 2 — Rule In / Rule Out
If the patient is an adult with type 1 diabetes, A1C ≤7.0%, expresses willingness and ability to use RT-CGM on a nearly daily basis, and has no contraindications (e.g., inability to wear sensor, lack of training capacity), proceed to Step 3; otherwise, do not recommend RT-CGM.
Decision: Proceed to classification or decline recommendation.
STEP 3 — Classify or Stratify
Classify the patient as having well-controlled T1DM (A1C ≤7.0%) and eligible for RT-CGM recommendation based on the gathered information.
Action: Confirm eligibility for RT-CGM prescription.
STEP 4 — Decide
Prescribe an RT-CGM device (e.g., Dexcom G6, Medtronic Guardian Connect), provide device-specific education on sensor insertion, calibration with SMBG, alarm settings, and data interpretation, and schedule a follow-up visit in 4 weeks to review glycemic data and device tolerance.
Action: Initiate RT-CGM therapy and arrange early follow-up.
Clinical Guardrails / Mimics / Pitfalls
Do not recommend RT-CGM for patients unwilling to perform occasional SMBG for calibration, those with unrealistic expectations of eliminating fingersticks, individuals with significant psychosocial distress that may impede device use, or patients lacking insurance/financial coverage for supplies. Avoid using RT-CGM as a sole basis for acute treatment decisions without confirmatory fingerstick glucose when symptoms do not match readings.
Pitfall: Overreliance on CGM trends without verifying hypoglycemia can lead to missed severe hypoglycemia.
Concrete Clinical Example
A 34‑year‑old woman with T1DM, A1C 6.8% on MDI, expresses interest in CGM to reduce hypoglycemia anxiety, confirms willingness to wear sensor daily, denies skin allergies, and performs SMBG 4 times/day. She meets criteria; RT‑CGM is prescribed, training provided, and follow‑up scheduled in 4 weeks.
Source: Diabetes Technology—Continuous Subcutaneous Insulin Infusion Therapy and Continuous Glucose Monitoring in Adults: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2016, DOI:10.1210/jc.2016-2534
TODO: consider adding scripts/calc.py for the endo-rtcgm-recommend-t1dm-well-controlled calculator